Insulin Pumps Market (2026-2032)

Insulin Pumps Market 2026-2032: AID Upgrades, Patch-Pump Adoption, Type 2 Expansion, and Recurring Consumables Reshape Insulin Delivery Revenue

The Global Insulin Pumps Market was valued at approximately USD 6.35 billion in 2025 and is projected to reach around USD 11.85 billion by 2032, expanding at a CAGR of approximately 9.3% during 2026–2032, according to MarketsandStats. Around 2.20 million people were actively using insulin pumps worldwide in 2025, with the user base expected to approach 3.90 million users by 2032.

Growth is being driven by the move toward automated insulin delivery, faster uptake of patch pumps, and broader use of pump therapy among insulin-treated people with Type 2 diabetes. Existing users are also adding to demand as older devices are replaced or upgraded to newer automated systems.  MarketsandStats estimates around 340,000 first-time pump starts and 380,000 replacement or upgrade placements in 2025, taking total patient-level pump placements to approximately 720,000 during the year.

The market also has a strong recurring-revenue base. Tandem Diabetes Care generated approximately USD 1.015 billion in 2025 sales, including around USD 550.6 million from supplies and other products, which was higher than its USD 464.1 million pump revenue. Insulet also benefits from repeated disposable Pod purchases across an installed base of more than 600,000 Omnipod users, while Medtronic continues to generate replacement and consumable demand through its large MiniMed pump population.

Competition is increasingly centered on AID capability, tubeless design, CGM interoperability, pharmacy reimbursement, and Type 2 indications. Medtronic Diabetes, Insulet, Tandem Diabetes Care, and Beta Bionics remain the main commercial players, while Sequel Med Tech is entering the U.S. market with a newer interoperable AID platform. These shifts are expanding the market beyond traditional durable pump sales and increasing the value of recurring supplies, software-linked therapy, and replacement cycles through 2032.

Which Segments Are Driving the Insulin Pumps Market?

By Product Type: Tubeless and patch pumps are emerging as the strongest product segment, generating approximately USD 3.05 billion in 2025 and projected to reach around USD 6.75 billion by 2032, expanding at nearly 12.0% CAGR. The active patch-pump user base is expected to increase from about 780,000 users in 2025 to 2.18 million by 2032, supported by rising preference for wearable systems and recurring disposable Pod use.

By Technology: Automated insulin delivery and hybrid closed-loop systems represented the largest and fastest-expanding technology segment, generating approximately USD 4.40 billion in 2025 and supported by nearly 1.50 million active users. Growth is being driven by replacement of conventional and sensor-augmented pumps with automated systems that combine continuous sensing, algorithm-based dosing, and insulin delivery.

By Diabetes Type: Type 1 diabetes remained the largest segment, contributing approximately USD 5.52 billion in 2025 with around 1.93 million active pump users. Type 2 diabetes is the faster-growing opportunity, increasing from about USD 830 million in 2025 to USD 2.84 billion by 2032 at approximately 19.2% CAGR, while the active-user base is projected to rise from roughly 270,000 to more than 1 million.

By Age Group: Adults accounted for approximately USD 4.95 billion in 2025, supported by around 1.67 million active users, and will remain the largest age segment through 2032. Growth is increasingly supported by adults with insulin-intensive Type 2 diabetes entering pump therapy alongside continued AID upgrades among existing Type 1 users.

By Sales Channel: DME and medical-device distributors remained the largest channel at approximately USD 3.15 billion in 2025, while retail and specialty pharmacies are expected to grow faster through 2032. Pharmacy-based reimbursement is reducing reliance on traditional DME fulfillment and creating a more accessible route for new pump starts and recurring supply purchases.

Why Is Automated Insulin Delivery Becoming the Main Revenue Pool?

Automated insulin delivery is becoming the most important technology segment because manufacturers are increasingly earning revenue from both new pump starts and upgrades of existing users. MarketsandStats estimates that AID and hybrid closed-loop systems represented about USD 4.40 billion, or nearly 69% of global insulin-pump revenue in 2025. Their share is expected to rise further through 2032 as conventional open-loop pumps and older sensor-augmented systems are progressively replaced.

Medtronic's Diabetes business generated USD 2.755 billion in FY2025, with the company specifically attributing U.S. growth to continued MiniMed 780G adoption and reporting low-20% international pump growth during the fourth quarter. The entire Diabetes revenue figure cannot be treated as insulin-pump revenue because it also contains CGM and other products, but the reported growth confirms that automated pump upgrades are already affecting commercial performance.

Tandem is following the same direction through Control-IQ-based systems, while Beta Bionics is expanding the market through its iLet platform. Beta Bionics reached 35,011 installed customers in 2025, up 129% from the prior year. Of its fourth-quarter new starts, 69% came from multiple daily injections, showing that automated systems are not simply shifting existing pump users between manufacturers. They are also bringing new patients into the pump category.

Market growth is therefore coming from both new patients starting pump therapy and existing users moving to newer automated systems, with each additional user also adding ongoing demand for Pods, infusion sets, reservoirs, and cartridges.  

Tubeless Pumps Are Changing Product Mix and Lifetime Revenue

Tubed insulin pumps still accounted for an estimated 52% of global market revenue in 2025, representing approximately USD 3.30 billion, while tubeless and patch pumps generated around USD 3.05 billion. Patch systems are expected to grow faster, potentially increasing their revenue share to approximately 57% by 2032.

Insulet provides the strongest evidence for this shift. The company generated approximately USD 2.7 billion in 2025 revenue, had more than 600,000 estimated global Omnipod users, operated in 25 countries, and reported Omnipod as the leading pump among new pump users in both the U.S. and Europe during 2025. Each disposable Pod provides up to three days of insulin delivery, creating repeated consumption rather than relying primarily on multi-year durable-pump replacement cycles.

Based on an estimated 780,000 global patch-pump users in 2025,  MarketsandStats estimates annual disposable Pod demand at approximately 92–94 million units. These Pods are recurring consumables and are not counted as separate insulin-pump placements.

Tubed pumps still serve an estimated 1.42 million users worldwide, creating annual demand for roughly 165–170 million infusion sets along with reservoirs and cartridges. This keeps tubed systems commercially important even as patch pumps gain users, because each pump placement continues to generate supply purchases throughout its use.

Type 2 Diabetes Is Opening a New Pump Growth Pool

Type 1 diabetes remained the primary revenue base in 2025, accounting for an estimated USD 5.52 billion, or approximately 87% of global insulin-pump sales. Type 2 diabetes contributed around USD 830 million, but it is expected to expand considerably faster as AID indications broaden and manufacturers target insulin-intensive patients who have historically relied on injections.

Beta Bionics provides direct evidence of this transition. Approximately 25%–30% of its fourth-quarter 2025 new patient starts were expected to involve people with Type 2 diabetes. Insulet's Omnipod 5 has also expanded AID access into Type 2 diabetes, while other suppliers are moving in the same direction.

MarketsandStats estimates approximately 270,000 active Type 2 pump users globally in 2025, compared with around 1.93 million Type 1 users. By 2032, the Type 2 installed base could exceed 1 million users, making it one of the largest sources of incremental pump placements during the forecast period.

Growth in the Type 2 segment is coming from insulin-treated patients shifting from multiple daily injections to insulin pumps. Wider approval and reimbursement of AID systems for Type 2 diabetes are increasing first-time pump placements, while each new user also adds ongoing demand for pump supplies.

Adults Will Capture Most Incremental Revenue Despite High Pediatric Penetration

Adults accounted for approximately USD 4.95 billion, or 78% of insulin-pump revenue in 2025, while pediatric and adolescent patients contributed around USD 1.40 billion. Adults generate the larger revenue pool because the insulin-treated population is much bigger and now includes a growing number of people with Type 2 diabetes moving onto pump therapy.

Pediatric pump use is already high in several mature markets. In Germany, 63.7% of children and adolescents with Type 1 diabetes used an insulin pump in 2022, while penetration reached 96.7% among children younger than three years. In these highly penetrated groups, growth comes less from first-time adoption and more from replacing older pumps, moving users onto AID systems, and continued purchases of pump supplies..

Pharmacy Fulfilment Is Beginning to Challenge the Traditional DME Model

Durable medical equipment distributors and medical-device channels remained the largest sales route in 2025, accounting for an estimated USD 3.15 billion, while retail and specialty pharmacies represented approximately USD 1.58 billion. Pharmacy sales are growing faster as more insulin pumps become available through pharmacy benefits rather than only through traditional DME coverage.

Beta Bionics shows how quickly pharmacy reimbursement is becoming a meaningful sales channel for insulin pumps Its Pharmacy Benefit Plan revenue increased 287% in 2025 to USD 24.4 million, while DME sales reached USD 75.8 million. By the fourth quarter, a low-30s percentage of new patient starts were already being reimbursed through pharmacy benefits. Tandem is also expanding pharmacy access in the U.S. This channel is important for market growth because easier pharmacy coverage can shorten the path to starting pump therapy and bring more eligible patients into the market.How Are the Seven Priority National Markets Developing?

United States - Type 2 Expansion and Pharmacy Access Create the Largest Revenue Opportunity

The United States represented approximately USD 2.85 billion of insulin-pump revenue in 2025, supported by an estimated 920,000 active users.  MarketsandStats projects the market to reach around USD 5.55 billion by 2032, expanding at approximately 10.0% CAGR.

U.S. growth is being driven by more patients moving onto AID systems, wider pump use among insulin-treated people with Type 2 diabetes, and easier access through pharmacy benefits. Tandem generated USD 706.9 million in U.S. sales in 2025 and shipped more than 86,000 pumps domestically, while Insulet has expanded Omnipod access to more than 47,000 U.S. pharmacies. Beta Bionics is also bringing new users into pump therapy from multiple daily injections, and Sequel Med Tech broadened competition with the nationwide U.S. rollout of its twiist AID system in March 2026.

These changes are increasing pump sales from both first-time users and existing users replacing or upgrading older systems, while every additional pump user also adds ongoing demand for Pods, infusion sets, reservoirs, and cartridges.

France - Verified User Volume Makes Patch-Pump Migration Highly Visible

France has one of the clearest national pump datasets. Health-insurance records show 92,872 adult and 18,598 pediatric pump users in 2024, taking the total to 111,470 users. New users accounted for 10.8% of adults and 14.9% of pediatric users, showing that the market is still adding first-time pump patients alongside an already large installed base.

MarketsandStats estimates the French Insulin Pumps Market at approximately USD 360 million in 2025, supported by around 118,000 active users, with revenue projected to reach nearly USD 630 million by 2032.

Patch pumps are already well established in France, accounting for 43.9% of adult and 44.9% of pediatric pump users in 2024. Future growth will therefore come less from basic patch-pump adoption and more from users moving to automated patch and hybrid closed-loop systems. This creates additional revenue from both system upgrades and continued Pod, infusion-set, and cartridge use.

Germany - Growth Is Moving Toward AID Upgrades

MarketsandStats estimates Germany's insulin-pump market at approximately USD 420 million in 2025, supported by around 125,000 active users, with revenue projected to reach approximately USD 730 million by 2032.

Pump use is already well established in several patient groups. Official surveillance shows that almost two-thirds of children and adolescents with Type 1 diabetes were using insulin pumps in 2022. This leaves less room for basic first-time adoption than in lower-penetration markets.

Growth is therefore coming increasingly from users replacing older pumps, adding sensor integration, and moving onto automated insulin-delivery systems. For suppliers, Germany remains attractive because a large existing pump population continues to generate replacement demand and recurring sales of infusion sets, reservoirs, cartridges, and other pump supplies.

United Kingdom - NHS Rollout Is Creating a Multi-Year Pump Upgrade Pipeline

MarketsandStats estimates the U.K. insulin-pump market at approximately USD 180 million in 2025, with revenue projected to reach around USD 390 million by 2032.

NHS England began a five-year phased rollout of hybrid closed-loop technology in April 2024. The implementation strategy identified around 26,000 existing Type 1 pump users and approximately 69,000 people considered eligible for pump therapy under earlier guidance.

The early stages of the rollout are expected to move many existing pump users onto HCL systems, while later phases should bring more first-time users into pump therapy as specialist capacity expands. NHS England is also supporting 75% of estimated incremental HCL costs for integrated care boards. This gives the U.K. a relatively clear path for both pump upgrades and new patient starts over the next several years.

Canada - Provincial Funding Has a Direct Effect on Pump Uptake

Canada remains an important insulin-pump market, although countrywide revenue and user data are less centralized than in France or the U.K. MarketsandStats expects steady growth through 2032 as provincial funding expands access and more existing users move onto AID systems.

The impact of reimbursement is already visible. Among adults with Type 1 diabetes, pump use reached 47.8% in provinces with government pump-funding programs, compared with 37.7% in provinces without them.

This difference shows how strongly public funding affects actual pump adoption. Wider provincial coverage can move more eligible patients from injections to pump therapy, while existing users create further demand through upgrades and recurring supply purchases.

Australia - Pump Growth Depends Heavily on Access and Affordability

Australia has a sizeable Type 1 diabetes population, but pump use remains limited by the way devices are funded.

More than 137,700 Australians were living with Type 1 diabetes as of March 2024, yet only around 24% of adults with Type 1 diabetes used an insulin pump. More than 80% of pump access was through private health insurance, according to Diabetes Australia.

MarketsandStats expects the Australian insulin-pump market to expand through 2032, but stronger growth will depend on improving access beyond privately insured patients. Wider funding support would allow more people who are clinically suitable for pump therapy to start treatment, increasing both device placements and recurring supply demand.

Japan - Low Pump Use Leaves Significant Room for Expansion

Japan remains less penetrated than several Western markets despite broad familiarity with diabetes technology. A nationwide claims study covering 119,104 people with Type 1 diabetes in FY2022 found that insulin-pump use increased from 5.9% in 2014 to 9.7% in 2022, while sensor-augmented pump use reached 4.3%. CGM adoption was much higher at 39.8%.

The gap between CGM and pump use is important for future growth. A large group of patients already use sensor-based diabetes technology but have not yet moved onto pump therapy.

Pump uptake was also higher at larger and certified treatment centers, while adoption varied considerably across regions. Growth in Japan will therefore depend on broader access to pump-capable centers, wider AID availability, and conversion of existing CGM users into integrated pump systems.

How Is Competition Shifting Across Insulin-Pump Platforms?

Competition in insulin pumps is no longer only about the pump itself. Companies are differentiating through automation, wearability, sensor compatibility, reimbursement access, and the amount of recurring revenue they can generate after the initial placement.

Insulet is leading the shift toward tubeless pumps, supported by more than 600,000 active Omnipod users and around USD 2.7 billion in 2025 revenue. Its disposable Pod model also gives the company a large base of repeat purchases after each patient starts therapy.

Medtronic Diabetes remains one of the largest players in automated pump therapy through MiniMed 780G and its integrated sensor platform. Its Diabetes revenue increased 10.7% in FY2025, with pump upgrades continuing to support growth in both the U.S. and international markets.

Tandem Diabetes Care continues to build around durable pumps, CGM compatibility, and recurring supplies. In 2025, revenue from supplies and other products exceeded pump revenue, showing how much of the company's sales now come from patients who are already using its systems.

Beta Bionics is smaller but is adding users quickly. Around 69% of its fourth-quarter new starts came from people previously using multiple daily injections, indicating that iLet is bringing new patients into pump therapy rather than relying only on users switching from another brand.

Sequel Med Tech adds another new option in the U.S. market. Its twiist AID system became broadly available in 2026 after a controlled launch, increasing competition among newer interoperable automated systems.

By 2032, competition will depend more on how well companies can move patients onto automated systems, keep them within their pump ecosystem, and support continued use through compatible sensors and recurring supplies.

Analyst Commentary

Insulin-pump development is moving toward smaller systems that place more control in the patient's phone and reduce the amount of hardware that must be carried or replaced. This is making pump therapy easier to start and less disruptive in daily use, especially for patients who previously avoided conventional tubed devices.

At the same time, newer patch platforms are moving away from fully disposable designs toward formats where the control or delivery hardware can be reused while only selected components are replaced. This can lower long-term treatment costs, reduce waste, and give manufacturers more flexibility in pricing and reimbursement discussions.

The advantage will increasingly go to systems that feel simpler in everyday use and cost less to stay on over time. That can help bring more first-time users into pump therapy while also encouraging existing users to move away from older devices.